Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antitrust safe harbor review

This article was originally published in The Gray Sheet

Executive Summary

Senate Judiciary/Antitrust Subcommittee Ranking Member Herb Kohl (D-Wisc.) indicates his support for reworking the federal health care antitrust guidelines in May 21 release announcing Hew Pate's appointment as DoJ Assistant Attorney General for Antitrust. Kohl and Subcommittee Chair Mike DeWine (R-Ohio) had requested DoJ and FTC reexamine the "antitrust safety zone" at a GPO hearing last April (1"The Gray Sheet" May 6, 2002, p. 9). "While the Federal Trade Commission has taken the lead in investigating this industry, the Antitrust Division's cooperation in revising the joint FTC/DOJ Health Care Guidelines will be essential to restoring competition to this vital sector," Kohl says...
Advertisement

Related Content

GPO Self-Regulation Prescribed As Alternative To Congressional Action
GPO Self-Regulation Prescribed As Alternative To Congressional Action
Advertisement
UsernamePublicRestriction

Register

MT018417

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel